Cancer Immunology and Immunotherapy (Record no. 214815)

MARC details
000 -LEADER
fixed length control field 02589nam a22003975i 4500
001 - CONTROL NUMBER
control field vtls004000410
003 - CONTROL NUMBER IDENTIFIER
control field UBDLIB
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240608194900.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130205s2011||||gw ||||||||||| |||||eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783642141362
-- 978-3-642-14136-2
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-3-642-14136-2
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (DE-He213)978-3-642-14136-2
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition information 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Dranoff, Glenn.
9 (RLIN) 185954
245 10 - TITLE STATEMENT
Title Cancer Immunology and Immunotherapy
Medium [electronic resource] /
Statement of responsibility, etc. edited by Glenn Dranoff.
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Berlin, Heidelberg :
Name of publisher, distributor, etc. Springer Berlin Heidelberg,
Date of publication, distribution, etc. 2011
300 ## - PHYSICAL DESCRIPTION
Extent XIII, 304p. 21 illus. in color.
Other physical details digital.
490 0# - SERIES STATEMENT
Series statement Current Topics in Microbiology and Immunology,
International Standard Serial Number 0070-217X ;
Volume/sequential designation 344
520 ## - SUMMARY, ETC.
Summary, etc. The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "first-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Oncology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cancer Research.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
9 (RLIN) 146659
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9783642141355
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Current Topics in Microbiology and Immunology,
International Standard Serial Number 0070-217X ;
Volume/sequential designation 344
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1007/978-3-642-14136-2">http://dx.doi.org/10.1007/978-3-642-14136-2</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification

No items available.

Powered by Koha